Status:
COMPLETED
Preference Tiotropium Respimat Study in COPD
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
18+ years
Brief Summary
In COPD the patient's ability to use inhalers correctly and their preference for the inhaler are both important factors in selecting an appropriate treatment for COPD. This is a cross-sectional study ...
Detailed Description
Purpose: Study Design:
Eligibility Criteria
Inclusion
- Inclusion criteria:
- All patients must sign an informed consent consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines prior to participation in the study and conducting any study procedures.
- Adult male or female patients with chronic obstructive pulmonary disease (COPD) for less than a year who follow usual clinical practice of the participant sites and who are on treatment with Spiriva® Respimat®, Hirobriz® Breezhaler® / Onbrez® Breezhaler® / Oslif® Breezhaler® for at least of 3 months but not more than maximum of 6 months before the informed consent date.
- Exclusion criteria:
- Previously included in this study or currently participating in another interventional study.
- Visual, cognitive, or motor impairment that as judged by the investigator does not allow the patient to independently read and complete the questionnaire.
- Patients who are treated simultaneously with both respiratory medications (Spiriva® Respimat® and Hirobriz® Breezhaler® / Onbrez® Breezhaler® / Oslif® Breezhaler®).
Exclusion
Key Trial Info
Start Date :
March 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01810692
Start Date
March 1 2013
End Date
March 1 2014
Last Update
March 26 2015
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site 13
A Coruña, Spain
2
Boehringer Ingelheim Investigational Site 5
Barcelona, Spain
3
Boehringer Ingelheim Investigational Site 6
Barcelona, Spain
4
Boehringer Ingelheim Investigational Site 8
Barcelona, Spain